Drugs and Devices

FDA approves Pomalyst for advanced multiple myeloma

On Feb. 8, 2013, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease has progressed after being treated with other cancer drugs. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares